Identification of drug–target interactions is an important process in drug discovery. Although
high-throughput screening and other biological assays are becoming available …

Gastric cancer is the fourth most common cancer globally, and is the second most common
cause of death from cancer worldwide. About three-quarters of newly diagnosed cases in …

Since their modern debut in 2004, 2-dimensional (2D) materials continue to exhibit scientific
and industrial promise, providing a broad materials platform for scientific investigation, and …

Despite success in hematologic malignancies, the treatment landscape of chimeric antigen
receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18. 2 (CLDN18. 2) …

Background The optimal perioperative chemotherapeutic regimen for locally advanced
gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and …

Background Weight reduction is essential for improving health outcomes in people with
obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose …

We report on a comprehensive analysis of the gut microbiomes of patients with
gastrointestinal (GI) cancer receiving anti–PD-1/PD-L1 treatment. The human gut microbiota …

Gains and losses in DNA methylation are prominent features of mammalian cell types. To
gain insight into the mechanisms that promote shifts in DNA methylation and contribute to …

Chromosomal double-strand breaks (DSBs) are resected by 5′ nucleases to form 3′
single-stranded DNA substrates for binding by homologous recombination and DNA …

A single biomarker is not adequate to identify patients with gastric cancer (GC) who have the
potential to benefit from anti-PD-1/PD-L1 therapy, presumably owing to the complexity of the …